Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

India’s Cipla Acquires First US Pharmaceutical Manufacturing Facility

XTALKS NEWS

Pharmaceutical Manufacturing

The acquisition was made in an effort to increase Cipla’s presence in the lucrative US market.

Share this!

February 22, 2016 | by Sarah Massey, M.Sc.

Global pharmaceutical company Cipla, has acquired two generic pharmaceutical manufacturing companies based in the US. “This acquisition is the second landmark acquisition in Cipla’s 80 year history – the first was Cipla Medpro, South Africa,” said a statement released by the company.

The Mumbai-based Cipla paid $550 million for InvaGen Pharmaceuticals, which has a generics manufacturing facility in Long Island, New York. InvaGen has 32 generic drugs on the market, with 30 more in development.

The deal also included Exelan Pharmaceuticals, a Lawrenceville, Georgia-based facility that markets InvaGen’s drugs toward the institutional and government sectors. Both plants have a combined approximate workforce of 500 employees.

The acquisition was made in an effort to increase Cipla’s presence in the lucrative US market. Currently, only 10 percent of the company’s annual revenues come from the US.



“InvaGen’s balanced portfolio, robust manufacturing base and strong R&D capabilities will act as lever to expand Cipla’s reach in the US market,” said Umang Vohra, CEO of Cipla. The company reported that revenues from the two US manufacturing facilities totaled $230 million in 2015.

Cipla used a UK-based subsidiary to complete the acquisition of the two sites. Both Cipla and its recently-acquired InvaGen plant have received their fair share of US Food and Drug Administration (FDA) attention. The agency issued a Form 483 to the New York plant just months before the Indian drugmaker announced their deal with InvaGen.

In the summer of 2015, the FDA also issued a Form 483 to a Cipla-owned facility in Indore. The FDA cited observations relating to a voluntary US recall of the company’s asthma drug, levalbuterol, after a degradant was identified in the product.


Keywords: Pharmaceutical Manufacturing, India, Generics


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
CAR-T Technology Could Be Effective Treatment For Blood Cancers

February 18, 2016 - The Annual Meeting of the American Association for the Advancement of Science (AAAS 2016) took place last weekend, and some exciting new progress has been made in the field of CAR-T therapies for blood cancer.


GlaxoSmithKline Receives $54.4 Million Fine In UK For Pay-For-Delay Deal

February 17, 2016 - According to a statement released by the UK’s Competition and Markets Authority (CMA) on Friday, the agency has fined GlaxoSmithKline for a pay-for-delay deal made over 10 years ago.


Novel Anti-Biofilm Compounds May Be Effective Against Drug-Resistant Bacteria

February 17, 2016 - A new class of anti-biofilm compounds extracted from marine-based microorganisms may be effective at treating drug-resistant bacteria that are commonly identified in patients with hospital-acquired infections.

 
THE XTALKS BLOG

Preparing For Disaster: 10 Things To Know About Mass Notification Systems and NFPA 72

Copyright © 2016-2017 Honeycomb Worldwide Inc.